Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia by Przybyla, Magdalena et al.
University of Wollongong 
Research Online 
Faculty of Science, Medicine and Health - 
Papers: part A Faculty of Science, Medicine and Health 
1-1-2016 
Disinhibition-like behavior in a P301S mutant tau transgenic mouse model 
of frontotemporal dementia 
Magdalena Przybyla 
University of New South Wales 
Claire H. Stevens 
University of New South Wales, stevensc@uow.edu.au 
Julia van der Hoven 
University of New South Wales 
Anne Harasta 
University of New South Wales 
Mian Bi 
University of New South Wales 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/smhpapers 
 Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences 
Commons 
Recommended Citation 
Przybyla, Magdalena; Stevens, Claire H.; van der Hoven, Julia; Harasta, Anne; Bi, Mian; Ittner, Arne; van 
Hummel, Annika; Hodges, John R.; Piguet, Olivier; Karl, Tim; Kassiou, Michael; Housley, Gary D.; Ke, Yazi D.; 
Ittner, Lars M.; and van Eersel, Janet, "Disinhibition-like behavior in a P301S mutant tau transgenic mouse 
model of frontotemporal dementia" (2016). Faculty of Science, Medicine and Health - Papers: part A. 
4059. 
https://ro.uow.edu.au/smhpapers/4059 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of 
frontotemporal dementia 
Abstract 
Frontotemporal dementia (FTD) presents clinically with behavioral changes including disinhibition. 
Mutations in the tau-encoding MAPT gene identified in familial cases of FTD have been used to generate 
transgenic mouse models of the human condition. Here, we report behavioral changes in a recently 
developed P301S mutant tau transgenic mouse, including disinhibition-like behavior in the elevated plus 
maze and hyperactivity in the open field arena. Furthermore, histological analysis revealed the amygdala 
as a primary and early site of pathological tau deposition in these mice. Taken together, 
neuropathological and behavioral changes in P301S tau transgenic mice resemble features of human 
FTD. 
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Frontotemporal dementia (FTD) presents clinically with behavioral changes  including disinhibition. Mutations in the 26 
tau-encoding MAPT gene identified in familial cases of FTD have been used to generate transgenic mouse models of 27 
the human condition. Here, we report behavioral changes in a recently developed P301S mutant tau transgenic mouse, 28 
including disinhibition-like behavior in the elevated plus maze and hyperactivity in the open field arena. Furthermore, 29 
histological analysis revealed the amygdala as a primary and early site of pathological tau d eposition in these mice. 30 
Taken together, neuropathological and behavioral changes in P301S tau transgenic mice resemble features of human 31 
FTD.  32 
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 1 
 2 
1. Introduction 3 
 4 
Frontotemporal dementia (FTD) is a term collectively used to describe a clinically, pathologically and genetically 5 
diverse group of neurodegenerative disorders. Clinically, FTD patients may show changes in behavior, language, 6 
cognition and motor function. The most common clinical phenotype is the behavioral variant of FTD (bvFTD), 7 
characterized clinically by changes in behavior and personality, including apathy and disinhibition  [19]. Early 8 
disinhibition in bvFTD may present as socially inappropriate behaviors, loss of manners, impulsive, rash and careless 9 
actions [17], with failure of inhibitory control [18]. Neuropathologically, FTD is characterized by the abnormal 10 
deposition of proteins in neurons and glia, including the microtubule associated binding protein tau, the transactive 11 
response DNA binding protein 43 (TDP-43), or less frequently, other proteins such as fused in sarcoma (FUS). 12 
Approximately one third of FTD cases are familial with the most frequent mutations found in the tau-encoding MAPT 13 
gene with tau pathology, and in GRN and C9ORF72 associated with TDP-43 deposition [10]. Interestingly, behavioral 14 
disinhibition is more frequent amongst MAPT, than GRN and C9ORF72 mutation carriers with familial FTD [21].  15 
 16 
Tau is an unstructured multi-domain protein that binds to microtubules to regulate their dynamics and intracellular 17 
transport processes [2]. Tau is predominantly found in the axon of neurons, although small amounts localize to the post -18 
synapse to regulate excitatory signaling [15]. Tau harbors over 80 potential phosphorylation sites, and in disease, it 19 
becomes aberrantly phosphorylated at many sites, which coined the term ‘hyperphosphorylated tau’ [11]. 20 
Hyperphosphorylation of tau compromises its binding to microtubules, resulting in accumulation of tau in the soma and 21 
dendrites of neurons [13]. Hyperphosphorylated tau is prone to oligomerize and form insoluble fibrillar aggregates that 22 
present as neurofibrillary tangles (NFTs), a common feature of FTD with tau pathology [5]. 23 
 24 
The identification of MAPT mutations in familial FTD has been instrumental in the generation of a significant number 25 
of transgenic mouse lines that develop functional deficits and NFT pathology (reviewed by [12]). We have recently 26 
reported TAU58/2 mice with neuronal expression of P301S mutant tau [24]. TAU58/2 mice present with motor deficits , 27 
and tau and neurofillament pathology reminiscent of human FTD with tau pathology. In the present study, we show that 28 
TAU58/2 mice develop early-onset disinhibition-like behavior and increased motor activity together with early NFT 29 
pathology in the amygdala, reminiscent of bvFTD.  30 
 31 
 32 
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2. Methods 1 
 2 
2.1. Mice 3 
TAU58/2 mice express the human 0N4R tau isoform with the P301S mutation under the control of the mouse Thy1.2 4 
promoter, as previously described by us  [24]. All animal experiments were approved by the Animal Ethics Committees 5 
of the University of New South Wales. All procedures complied with the statement on animal experimentation issued 6 
by the National Health and Medical Research Council of Australia.  7 
 8 
2.2. Histology  9 
Three, 6 and 12 month-old male TAU58/2 transgenic mice (n=4-9) and non-transgenic littermates (n=3-6) were used 10 
for histological analysis. At the desired age, mice were anesthetized and transcardially perfused with phosphate 11 
buffered saline (pH 7.4) to remove blood. Brains were removed and immersion fixed in 4% paraformaldehyde , 12 
processed in an Excelsior tissue processor (ThermoFisher, Waltham, MA, USA), embedded in paraffin and sectioned in 13 
the coronal plane at 3-8m. One-2 Sections per mouse corresponding to approximately -2.54 mm relative to Bregma 14 
were stained with antibodies against tau phosphorylated at Ser214 (pS214, Abcam) and Ser422 (pS422, Abcam), and 15 
with Gallyas silver impregnation to reveal NFTs  composed of insoluble tau aggregates , using previously published 16 
procedures [14]. Brain sections stained with pS422 and pS214 were scanned on a Scanscope Aperio FL (Leica 17 
Biosystems). One fluorescent channel Alexa Fluor 488 (Excitation 485/20-25, Emission 521/25) was imaged with an 18 
exposure time of 320 ms, which was kept consistent across all slide imaging. The number of pS422 and pS214-positive 19 
neurons were counted throughout the amygdala. Neurons with bright (high) staining signal for pS214 were counted 20 
separately of those neurons with less intensive (low) staining. Brightfield microscopy was performed with an Olympus 21 
BX51 (USA) microscope equipped with a DP70 color camera. The number of Gallyas silver positive NFTs, identified 22 
by black colour, and neuronal size and shape, were counted throughout the amygdala. Olympus CellSens software was 23 
used to delineate the regions of interest, and area measurements automatically calculated. All cell counts were 24 
converted to a density value (cells/mm2). For all quantitation, repeated measures on different days gave an inter- and 25 
intra-rater variability of <5%. 26 
 27 
2.3. Behavioral testing  28 
2.3.1. Elevated Plus Maze  29 
Anxiety and disinhibition-like behavior were tested in 3, 6 and 10 month-old male TAU58/2 mice (n=10-18) and non-30 
transgenic littermates (n=7-17) in an elevated plus maze (Ugo Basile), consisting of two open and two closed arms 31 
(each 35cm x 5.5cm), as well as a central platform (5.5cm x 5.5cm), arranged in a plus shape and elevated 60cm above 32 
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the ground. Mice were acclimatized to the room for 1 hour prior to testing, then placed on the central pla tform facing an 1 
open arm and recorded for 5 minutes. Recordings were done at 210-215 lx (open arm), 130-140 lx (closed arm). Videos 2 
were analyzed using the AnyMaze software (Stoelting) by a person blinded to the genotypes .  3 
 4 
2.3.2. Open Field  5 
Activity, anxiety and exploration pattern were tested in 3, 6 and 10 month-old male TAU58/2 mice (n=6-17) and non-6 
transgenic littermates (n=6-13) in an open field arena. Mice were individually placed at the periphery of a box (40cm x 7 
40cm) in an enclosed cupboard and their movement recorded for 10 minutes. Recordings were done at 200 lx. Videos 8 
were analyzed using the AnyMaze software by a person blinded to their genotypes. For analysis, the box was divided 9 
into an outer and inner zone, where the inner zone was represented by a 22.5cm x 22.5cm square in the center of the 10 
box.  11 
 12 
2.4. Statistical analysis 13 
All statistical analysis was done using the Graphpad Prism 6.0 software (GraphPad, La Jolla, CA, USA) using either 14 
Student’s t-tests for comparison of two data sets, analysis of variance (ANOVA) for comparison of more than two data 15 
sets or two-way ANOVA for comparison across time. P vales of below 0.05 were considered significant. All values are 16 
presented as mean  standard error of the mean.  17 
 18 
3. Results 19 
3.1. Amygdala is an early site of tau pathology in TAU58/2 mice 20 
TAU58/2 mice express P301S mutant human 0N4R tau under the control of the murine Thy1.2 promoter in CNS 21 
neurons, and we have previously reported motor deficits in this line when challenged in different test paradigms  [24]. In 22 
the present study, we determined whether TAU58/2 mice recapitulate features of bvFTD, focusing on disinhibition and 23 
risk taking behavior.  24 
 Atrophy of the amygdala is observed in the early stages of FTD [16], and considerable tau pathology has been 25 
reported in the amygdala of patients with FTD and related neurodegenerative disorders [6, 26]. While we have 26 
previously assessed tau pathology in TAU58/2 mice [24], this analysis has not included the amygdala. Therefore, we 27 
determined tau pathology in the amygdala of young (3 months), adult (6 months) and aged (12 months) TAU58/2 mice, 28 
using both immunohistochemical staining for phosphorylated tau and Gallays silver staining of NFTs (Figure 1). 29 
PS214 is known to be a marker of early tau involvement, while pS422 is known to be affected later in disease course  30 
[8]. In line with this, abundant pS214-positive neurons were already seen in young TAU58/2 mice, with the number of 31 
intensely stained neurons significantly increasing in adult and aged transgenic mice (Figure 1A and 1B). In contrast, 32 
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only a few pS422-positive neurons were seen in the amygdala of young TAU58/2 mice, but their numbers significantly 1 
increased with age (Figure 1C and 1D). Similarly, NFTs were present in small numbers in young TAU58/2 mice, and 2 
significantly increased over time resulting in extensive pathology by 12 months of age (Figure 1E and 1F). Non-3 
transgenic littermates were negative for phosphorylated tau and  NFT pathology. Taken together, progressive 4 
hyperphosphorylated tau and NFT pathology manifests early in the amygdala of TAU58/2 mice. 5 
 6 
 7 
3.2. Behavioral changes in TAU58/2 mice 8 
The amygdala is an important area for behavior control [20]. To determine the impact of transgenic P301S mutant 9 
tau expression on the behavior in TAU58/2 mice, we subjected transgenic mice and non-transgenic littermates to 10 
elevated plus maze (EPM) and open field (OF) testing (Figure 2 and 3). Young (3 months), adult (6 months) and aged 11 
(10 months) TAU58/2 and non-transgenic control littermate mice were tested. EPM testing revealed that already young 12 
TAU58/2 mice spent significantly more time in the open arms than their non-transgenic littermates (Figure 2A and 2B). 13 
Similarly, both adult and aged TAU58/2 mice spent more time in the open arms  than their respective non-transgenic 14 
littermates. When comparing TAU58/2 mice across ages, we found that aged spent significantly more time in the open 15 
arms than young and adult mice (Figure 2B). The time when mice emerged for the first time from the closed into the 16 
open arms was significantly reduced in TAU58/2 mice compared to non-transgenic littermates of all ages (Figure 2C). 17 
In all age groups, the time animals were mobile and distances travelled during testing were comparable in TAU58/2 and 18 
non-transgenic mice, showing motor competency (Figure 2D). 19 
Next, we exposed young, adult and aged TAU58/2 mice, and the respective non-transgenic littermate controls, to a 20 
novel OF arena and recorded their exploration pattern and locomotion activity continuously over 10 minutes  (Figure 3). 21 
Both young and adult TAU58/2 and their non-transgenic littermates travelled comparable distances during testing 22 
(Figure 3A and 3B). However, distance travelled and time mobile during testing were significantly higher in aged 23 
TAU58/2 mice compared to non-transgenic littermate controls, which presented reduced activity compared to younger 24 
mice (Figure 3B and 3C). The exploration paths in the OF arena were comparable between all age groups tested 25 
(Figure 3A), with similar frequent entries into the inner zone of the arena (Figure 3D). Taken together, TAU58/2 26 
present with progressive early-onset deficits in the EPM, while changes in the OF are of late onset.  27 
 28 
4. Discussion 29 
In the present study, we showed that tau pathology in the amygdala of TAU58/2 mice is of early onset and 30 
progressive. EPM testing revealed disinhibition/reduced anxiety already in young TAU58/2 mice, while deficits in the 31 
exploration and hyperactivity in the OF test were of later onset.  32 
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Previous studies have not assessed tau pathology in the amygdala of TAU58/2 mice  [23, 24]. While we found earlier 1 
that tau pathology presents in hippocampus, cortex and brain stem of TAU58/2 mice [24], the present study would 2 
suggest that the amygdala is a primary site of NFT pathology in this tau transgenic line . Accordingly, numbers of NFTs 3 
in the amygdala of aged TAU58/2 mice were approximately 4-fold those we reported earlier for the hippocampus and 4 
2-fold higher compared to numbers in the brain stem [24]. Interestingly, significant atrophy of the amygdala has been 5 
found in the brains of FTD patients  [3, 4]. Considering the importance of the amygdala in controlling behavior [20], 6 
early onset of pathology and behavioral changes in the EPM in TAU58/2 mice suggest a contributing role to the clinical 7 
presentation of FTD. However, other brain areas may contribute to the observed deficits  including cortical regions [1], 8 
despite lower levels of tau pathology compared to the amygdala in TAU58/2 mice [24]. 9 
In parallel to the early tau pathology in the amygdala, we show here already in young TAU58/2 mice decreased 10 
anxiety behaviour consistent with disinhibition during EPM testing. Increased impulsivity/disinhibition-like behavior of 11 
TAU58/2 mice is furthermore supported by a reduced latency to leave the enclosed arms of the EPM. For comparison, 12 
abnormal and progressive behaviour in the EPM, with increased time spent in the open has been reported in other tau 13 
transgenic mouse models of FTD, some associated with widespread tau pathology (including in amygdala and cortex) 14 
[6, 7, 9, 22, 25]. Although the youngest group of TAU58/2 mice tested already showed marked EPM deficits, this 15 
further progressed as mice aged. In contrast to early EPM deficits in young TAU58/2 mice, exploration and activity in 16 
the OF were not altered at 3 and 6 months of age, but only became apparent in aged mice. TAU58/2 and non-transgenic 17 
mice similarly avoided the inner zone of the OF indicating similar anxiety levels, and further supporting that deficits in 18 
the EPM rather result from disinhibition than reduced anxiety. Similar behaviour in the OF has been reported for other 19 
tau transgenic lines [6]. Disinhibition and lack of emotional control with inappropriate social behaviour is a lead 20 
symptom of bvFTD [17, 18], resembled by TAU58/2 mice. 21 
A very recent publication reported early increases in risk-taking behavior in young TAU58/2 when tested in the 22 
light/dark paradigm, but no changes to exploration and activity in the OF arena, including in aged mice [23]. Our study 23 
found similar behavior in young TAU58/2 mice using the EPM paradigm, as well as hyperactivity in the OF in aged 24 
mice, consistent with findings in other tau transgenic lines [6, 25]. The differences in OF behavior of TAU58/2 mice 25 
between studies may be due to alternative testing equipment and procedures, subtle differences in the genetic 26 
backgrounds or distinctive husbandry conditions. 27 
 28 
5. Conclusion 29 
Taken together, we found early-onset and progressive disinhibition-like behavior in TAU58/2 mice, together with 30 
early NFT pathology in the amygdala, resembling clinical presentations and neuropathology of bvFTD with tau 31 
pathology. We propose that EPM testing correlates with early tau pathology in the amygdala and is a reliable and quick 32 
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behavioral testing method to determine functional deficits in TAU58/2, which should be included in studies aiming at 1 
modifying disease progression, for example by crossing with other genetically modified mouse lines or by 2 
administering therapeutic compounds. 3 
 4 
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Figure legends  1 
 2 
Figure 1 Progressive tau pathology in the amygdala of TAU58/2 mice. 3 
(A) Representative immunofluorescence (IF) staining of the amygdala of young, adult and aged TAU58/2 mice, using 4 
an antibody specific for tau phosphorylated at serine 214 (pS214). Arrows indicate neurons with ‘high’ staining 5 
intensity, while arrow heads indicate cells with ‘low’ staining intensity. No staining was observed in non-transgenic 6 
brain tissue. Scale bar, 50µm. 7 
(B) Quantification of numbers of pS214-positive cells with low (pS214low) and high (pS214high) staining intensity per 8 
mm2 (*, p<0.05; **, p<0.01; ***, p<0.001; n=4-9).  9 
(C) Representative IF staining of the amygdala of young, adult and aged TAU58/2 mice, using an antibody specific for 10 
tau phosphorylated at serine 422 (pS422). No staining was observed in non-transgenic brain tissue. Scale bar, 50µm. 11 
(D) Quantification of numbers of pS422-positive cells per mm2 (*, p<0.05; ***, p<0.001; n=4-9). 12 
(E) Representative Gallyas silver staining of NFTs (black) in the amygdala of young, adult and aged TAU58/2 mice. 13 
No staining was observed in non-transgenic brain tissue. Scale bar, 50µm. 14 
(F) Quantification of numbers of NFTs per mm2 (***, p<0.001; ****, p<0.0001; n=6-9). 15 
 16 
Figure 2 Early-onset disinhibition-like behavior in TAU58/2 mice. 17 
(A) Example traces of young, adult and aged TAU58/2 mice and non-transgenic littermate controls in the EPM, 18 
comprising two open and two closed (grey) arms. 19 
(B) Quantification of relative time spent in the open arms, closed arms and center in the EPM (*, p<0.05; **, p<0.01; 20 
***, p<0.001; ****, p<0.0001; n=10-18). 21 
(C) Quantification of first time to emerge from the closed arms of the EPM into the open (*, p<0.05; **, p<0.01; n=10-22 
18). 23 
(D) Quantification of time mice were mobile and total distance travelled during EPM testing (n=10-18). No significant 24 
differences were found. 25 
 26 
Figure 3 Increased activity in aged TAU58/2 mice. 27 
(A) Heat map tracing of young, adult and aged TAU58/2 mice and non-transgenic littermate controls  in the OF.  28 
(B) Quantification of distance travelled in the OF over 10 min (**, p<0.01; n=6-10). 29 
(C) Time aged mice were mobile each min in the OF over 10 min (*, p<0.05; n=6-10). SEM are depicted as shaded 30 
bars. 31 
Page 10 of 10 
(D) Quantification of time spent in the inner zone in the OF over 10 min (n=6-10). No significant differences were 1 
found. 2 
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Przybyla et al. Figure 3
